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Abstract
Osteoporosis affects tens of millions of people in America and is the most common disease of the bones. New treatments are
constantly sought, as existing ones have documented side effects.This review seeks to pinpoint the most effective and safe treatment for osteoporosis by looking at head-to-head trials and research regarding combination therapies. This review also looks at
the effectiveness of non-pharmacologic treatments and whether any options are beneficial. The importance of an open patient/
provider relationship proves itself, as many medications and treatment plans depend on personal factors that need to be measured and weighed by a medical professional together with the patient.
Introduction
Osteoporosis is a condition in which the density of bones
decreases and their overall quality deteriorates. Mainly affecting postmenopausal women and men over the age of
50, osteoporosis puts people at risk for fractures, disability, and in the case of hip fractures, even mortality (Panula
et al., 2011).
Bones are dynamic and are constantly being remodeled.
The remodeling process accomplishes two objectives: it
repairs micro-cracks in bone that result from everyday
use, and it also re-aligns and reshapes bone to better
handle the stress put on it. The two main cells involved
in this process are osteoblasts, responsible for building
bone, and osteoclasts, responsible for removing old bone
and the resorption of Ca2+ back into the bloodstream.
Bones are extremely important for maintaining homeostasis because they are reservoirs of calcium. Muscles and
the nervous system also use calcium ions in their basic
functions, and when there is a shortage of calcium in the
bloodstream, bone resorption is triggered. The thyroid
and parathyroid glands control release of calcium from
bone into the blood through endocrine signaling.
As we age, different factors increase the risk of osteoporosis. Vitamin and mineral deficiency, more commonly
seen in those over 65 years old, contributes to bone loss
as vitamin D3 and calcium are necessary for bone health.
Stem cells differentiate into osteoblasts at a slower rate
over time. Additionally, menopause leads to the decrease
of estrogen, the sex hormone responsible for inhibiting
osteoclast activity, thereby increasing the risk of osteoporosis in women over 45 years old.
There are numerous pharmacologic treatments approved by the FDA for both prevention and treatment
of osteoporosis. These drugs vary greatly in their mechanisms and pathways but fall into two general categories. Some are anti-resorptive, preventing osteoclast
activity, and others are anabolic, causing osteoblast activity. Unfortunately, these drugs come with side effects
and health risks. The National Osteoporosis Foundation
recommends clinicians to use the pharmacological approach only after attempting treatment through diet,
exercise, physical therapy and fall prevention guidance.
However, once a patient presents with a fracture, drugs
54

are recommended immediately (Cosman et al., 2014).
The first line of treatment recommended are bisphosphonates, such as alendronate and zoledronic acid, which
are anti-resorptive drugs that cause osteoclast apoptosis. A more expensive and effective drug is teriparatide
(TPTD), the first anabolic drug for osteoporosis. It encourages osteoblast activity and results in greater bone
density. Each of these treatments present with their own
risks and cannot be used indefinitely, therefore there is
a need to maximize the benefit of each treatment. This
review is aimed at determining the best treatment of osteoporosis to date.
Methods
Articles were obtained using Touro College’s online library and PubMed database using keywords such as “osteoporosis,” “bisphosphonates,” “teriparatide,” and other
key terms.
Diagnosis
There are a few major predictors of osteoporosis. The
age of a patient is a factor, as most of those with osteoporosis are above the age of 50. A history of fractures
and maternal history of fractures also provides a glimpse
of future bone-related problems.The OFELY study identified left hand grip strength as an indicator, along with low
physical activity and low bone mineral density (Albrand
et al., 2003). Patients who have experienced a fracture
or who are considered at risk for fracture are advised
to have a dual energy x-ray absorptiometry (DEXA) test
performed to measure their bone mineral density (BMD).
A score is given based on comparison to DEXA results
of 30-year-olds of the same race and gender. This frame
of reference allows the clinician to assess whether medication is the correct approach to manage a patient’s osteoporosis. A BMD T-score of ≤-1.0 in standard deviation
indicates osteopenia, the stage of bone density decline
that precedes osteoporosis. A score of ≤-2.5 is considered osteoporosis. Measures of the hip, femoral neck, and
the vertebral column are taken, and their scores may be
independent of each other. Using these numbers alone is
not an appropriate way to gauge whether medication is
correct. Patient lifestyle and diet should be considered,
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as a sedentary individual or a patient who smokes is at
risk for a sharper decline in bone density (Krall, DawsonHughes, 1999) and should be monitored more often than
a physically active or non-smoking patient.
Pharmacologic Treatment
In the event medication is deemed appropriate, the numerous options available are both a blessing and a hurdle.
No single medicine has proven completely effective or
safe for long term use. As such, new remedies are constantly being sought and extensive research has been
done to assess the efficacy of each drug and drug combination as well as the appropriate duration of treatment.
The drugs currently available fall into two main categories: anabolic and anti-resorptive. The anabolic drugs increase osteoblast activity, thereby directly building bone.
The anti-resorptive drugs stop osteoclasts from destroying older bone by inducing apoptosis in osteoclasts.
In the category of anti-resorptive drugs are bisphosphonates. These drugs disrupt the resorptive action of
osteoclasts by inducing osteoclast apoptosis. The osteoblasts will continue to build bone and that results in
greater BMD. Alendronate (Fosamax) is usually the first
medication given to an osteoporotic patient, and as Black
et al. (2006) found, its effects continue even after discontinuation. Patients who took Alendronate for five years
continued to have decreased markers for bone turnover
for another five years. Taking bisphosphonates together
with an anabolic drug, such as teriparatide (TPTD), a PTH
analog, does not show any synergistic benefit, and using
a bisphosphonate might even limit the anabolic effect of
teriparatide (Black et al., 2003). However, Cosman et al.
(2011) asserts that the combination of teriparatide and
zoledronic acid (Reclast, a bisphosphonate) is better
than either one alone. In a study done by Finkelstein et
al. (2003), one group took only alendronate, and another
group was given teriparatide 6 six months after starting
alendronate. The results were in favor of alendronate
monotherapy. Finkelstein comments that the study did
not explore whether combination therapy would be
better if the two drugs were started at the same time.
Muschitz and colleagues researched what would happen
if alendronate were given in conjunction with TPTD a few
months after TPTD therapy was started, as opposed to
TPTD monotherapy. The results showed that combination therapy was more effective (Muschitz et al., 2013).
This would indicate that TPTD needs time to start building bone and only then will the combination of an anti-resorptive have an effect greater than TPTD alone. In
Cosman’s research the drug combination was started at
the same time. One may explain such results by conjecturing that distribution of zoledronic acid inside the body

works differently than alendronate and allows the TPTD
to start building bone before the anti-resorptive starts
working. However, this is not true because research has
shown that zoledronic acid affects the body faster than
alendronate does (Saag et al., 2007). It would seem that
there is a benefit to taking zoledronic acid together with
TPTD but not alendronate with TPTD.
The anabolic drugs available include teriparatide
(Forteo) and abaloparatide (Tymlos). These drugs are
recombinant parathyroid hormone, which stimulates the
process of bone remodeling. Though continuous release
of PTH in the body releases calcium from the bones, weakening them, spaced doses of these PTH analogs stimulate
the entire bone remodeling unit. The result is increased
bone formation. This is the basis for the hypothesis that
bisphosphonates do not work together with anabolic
drugs. Bisphosphonates inhibit osteoclasts, and anabolics
might rely on osteoclasts as a part of the remodeling unit
to result in a net gain of bone. Hagino et al. (2021) found
a discrepancy between once-daily administered teriparatide and once-weekly administration. Hagino discovered that although once-daily increases bone formation,
once-weekly also decreases bone resorption. We know
that the amount of the drug given plays an important role,
and a higher dose will result in greater bone formation
but also greater bone resorption; at times leading to a
net loss of bone density (Neer et al., 2001). The results
of Hagino et al. indicate that even at high doses, a once
weekly injection of teriparatide prevents bone resorption
besides for increasing bone formation.Whether once daily
or once weekly injections are more effective is a source
of dispute between the results of different trials. The trial
led by Hagino, called the JOINT-05 trial, indicated that
once weekly is more effective as compared to the once
daily VERO trial, led by Kendler. However, the VERO trial
considered a patient who took 75% of the injections over
the course of the study to be compliant (Kendler et al.,
2017). In that case, once-daily administration may indeed
be more effective if taken correctly. Additionally, only 29%
of participants followed through in the JOINT-05 trial,
and therefore the data is less reliable for comparison. In
both trials teriparatide was proven to be more effective
than bisphosphonates at preventing fractures. Both trials
ended the treatment before 24 months because trials in
animal models show a risk of osteosarcoma if teriparatide is taken for more than two years. No serious adverse
effects were reported, making another case for the use of
teriparatide over bisphosphonates.
Recently, Romosozumab (Evenity), a newcomer to the
market, appeared to accomplish both goals of anabolism
and anti-resorption. Romosozumab is a monoclonal
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antibody that binds sclerostin, a protein produced by osteoclasts that inhibits bone growth. It too, was compared
head-to-head with alendronate and increased bone mass
more than alendronate (Saag, et al. 2017). In a study comparing it to teriparatide, Romosozumab performed better
at increasing BMD and bone mineral content (Genant et
al., 2017). That study was very small, so it is hard to consider the results as a final judgement.The authors attempt
to justify their small numbers with the use of quantitative
computed tomography (QCT) which is a more accurate
way of imaging and might reflect the results of a larger
trial. Romosozumab is administered once monthly as an
injection and is to be used for only 12 months due to risk
of cardiovascular issues.
Denosumab (Prolia), another monoclonal antibody,
functions as an anti-resorptive by binding to receptor
activator of nuclear factor-kappa B ligand (RANKL). This
receptor normally activates its counter-protein RANK
which in turn activates osteoclasts. By binding to RANKL,
denosumab stops resorption and increases BMD at a
rate similar to zoledronic acid. The two were compared
head-to-head in a large trial by Choi et al. (2017). Both
showed equal safety and positive effect on BMD and very
few cardiovascular events. However, the mean age in the
study was 63, and therefore would not reflect the safety
of those substantially older and taking these drugs.
Denosumab can cause hypocalcemia and therefore
must be taken with calcium and vitamin D3 supplements.
Patients who discontinue denosumab lose BMD quickly
and are at great risk for a rebound fracture. It is for this
reason that those who stop taking denosumab are given a

different osteoporotic drug (Cosman et al., 2014).
Denosumab and zoledronic acid are compared because
of the frequency and route of administration: subcutaneous injection once or twice a year. Frequency and route
of administration are important factors in treating osteoporosis because patient adherence is lower with oral
bisphosphonates.They are not absorbed well and so must
be taken on an empty stomach and the patient must not
lie down for a period of time after taking them. They can
cause esophageal ulcers and other GI ailments (Cosman
et al, 2014). Denosumab and zoledronic acid are both injections which are absorbed much more efficiently. Their
doses are spaced widely, so although they may cause a
certain amount of discomfort, they are tolerated better
than daily oral or subcutaneous administration.
One concern for all anti-resorptives is the risk for atypical femoral fractures (Shane et al., 2014). These fractures
are caused by the decrease in bone remodeling. When
osteoclasts are inhibited, they do not clear away old bone
and the infrastructure upon which new bone is built can
fracture even without trauma. However, these fractures
are rare and the benefits of taking bisphosphonates or
denosumab and preventing an osteoporotic related fracture outweighs the risk of an atypical femoral fracture.
A summary of these drugs, their use, duration, and side
effects is presented in Table 1.
Though the possible side effects for each drug might
dissuade patients, most are relatively rare. It is notable
that in every clinical trial there were those who discontinued the treatment simply due to the discomfort of
taking the drug. Indeed, a drug such as zoledronic acid

Drug

Brand Name

Prevention or
Treatment

Route of Administration/ Frequency

Type of
Drug

Recommended
Duration

Main Outcome

Side Effects

Alendronate

Fosamax

Prevention
(lower dose)
and treatment

Oral
(IV not FDA approved)
/ Daily and weekly
dosages available

Bisphosphonate

5-10 years

Anti-resorptive.
Induces osteoclast apoptosis

GI perforation, ulcers,
esophageal ulcers
Rare: osteonecrosis of
jaw, atypical femoral
fracture

Teriparatide

Forteo

Treatment only

Subcutaneous / daily

Recombinant PTH
analog

2 years

Builds bone
by stimulating
entire remodeling unit.

Hypercalcemia, nausea,
pain
Rare: osteosarcoma

Denosumab

Prolia

Treatment only

Subcutaneous / once
every 6 months

Monoclonal
antibody

Up to 10 years

Anti-resorptive,
binds to RANKL,
stops osteoclast
formation

Hypocalcemia, Muscle
and joint pain
Rare: osteonecrosis
of jaw

Romosozumab

Evenity

Treatment only

Subcutaneous / once
a month

Monoclonal
antibody

1 year

Binds sclerostin,
anti-resorptive
and anabolic.

Rare: cardiovascular
events

Zoledronic
Acid

Reclast

Prevention
(lower dose)
and treatment

IV / one time or once
yearly (lower dose)

Bisphosphonate

2 years

Same as alendronate

Flu-like symptoms,
muscle and joint pain

Table 1. Information based on National Osteoporosis Foundation’s Clinician’s Guide to Prevention and Treatment of Osteoporosis (Cosman et
al., 2014). Denosumab was found to be safe for up to 10 years (Bone et al., 2017).
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causes flu-like symptoms. To judge which drug is the best
way to treat osteoporosis one might need to consider
side effects that make it difficult to take the drug. The
clinician should discuss the side effects with the patient
and explain how the benefits outweigh the short-term
discomfort.
Non-Pharmacologic Treatment
Osteocytes act as mechanoreceptors and signal bone
modeling in areas of high stress. This greatly contributes
to the thickness of cortical bone and the unique formation of trabecular bone each person may have. Exercise
activates the osteocytes and builds bone. However, as
a treatment for osteoporosis, it is difficult to prescribe
exercise because of the numerous factors surrounding
it. The intensity, type, and amount of each exercise and
constitution of each individual plays a role in determining
the efficacy of the exercise in building bone.
The LIFTMOR trial sought to demonstrate the effectiveness of high resistance training (HiRT) over a more
aerobic, balance-focused exercise program. Using DEXA
and a 3D imaging program, the authors verified that a
high resistance training program, marked by higher loading and power lifting, will increase BMD significantly more
than aerobic training (Watson et al., 2018).The LIFTMOR
trial proved that with correct supervision, exercise
could provide an increase in BMD and prevent fractures.
However, the trial did not include those with cardiovascular problems, and the mean age was 65 ±5, leaving a
large population for whom exercise may not be a solution. Additionally, the need for careful supervision during
the program may explain why medicine is the first line of
treatment for osteoporosis. It is of note that regarding
the safety of this program only one out of a hundred and
one participants suffered a minor injury that required
only a week of rest from the program. Only 7 participants experienced a fall during the 8-month period; none
of the falls resulted in a fracture. All the participants had
low bone mass, so this indicates that all forms of exercise
performed, both balance and HiRT, had a positive effect
on fracture occurrences.
Besides for the benefit of high resistance exercise, a
trial was done to ascertain whether the rate of mechanical loading also affected bone density. The participants
were approximately 4.5 years post-menopause and were
all accustomed to high resistance training. Two groups
were formed: one performing exercise with a slower rate
of loading and unloading, and another group performing
the contraction part of each exercise as quickly as possible. Though an increase in BMD was noted in the second
group, referred to as the power training (PT) group, it

was only noted during the first year of the two-year trial,
and only at the spine (von Stengel et al. 2007).Von Stengel
hints that such results can be explained by the bones and
muscles becoming accustomed to the rapid rate and the
osteocytes no longer activating bone growth in response.
If there had been a rest period and the exercise subsequently continued, it is possible there would have been an
increase in BMD.
Fall prevention and balance training are always recommended (Cosman et al. 2014) and will have a positive effect for those with osteopenia and osteoporosis.
Exercise as performed in the above trials is not an appropriate treatment for those with advanced osteoporosis or those who will not have supervision. But there
remains an option for the elderly that does not involve
medication – whole body vibration (WBV). Research into
this technology shows that even the elderly can reap the
benefits of mechanical stimulation using WBV. WBV involves a platform with a vibrating plate that delivers a low
magnitude vibration that is barely felt yet causes anabolic
growth via stimulating the bones (Rubin et al. 2001). A
three-year study, however, did not show any benefit to
using the WBV platform. The authors of that study conjecture that the large age range, a mean of 82.5 +/-8.1,
might have interfered with their results.They also hypothesized that though the technology showed a benefit for
younger patients at the same magnitude (Rajapakse et
al, 2021), older individuals may require higher intensity
(Kiel 2015). It seems that the study by Kiel et al. (2015)
was done in a way to ensure safety, but the magnitude
was much lower than the standard allowed. In addition,
the participants only used the platform for ten minutes
a day, whereas from a safety standpoint they could have
used it for longer. Also, those who exercise spend more
than ten minutes daily doing so, so if WBV can serve as a
replacement it should be prescribed for longer durations.
The study done by Rajapakse et al. (2021) holds a certain
amount of weight over similar studies that did not show
as much benefit in WBV because of the adherence level.
In Rajapakse’s study, the devices were fitted with a sensor
that measured usage, supplying more accurate information than self-reporting.
Vitamins
The use of vitamins alone to prevent fractures serves the
benefit, like exercise, of avoiding side effects from medication. Vitamin D3 is necessary for bone growth and is
often given together with calcium, also a component of
bone growth. In a three-year study in Denmark, where
most people do not produce enough Vitamin D3 from
sunlight alone, Vitamin D3 and calcium together showed
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a 16% reduction in fractures (Larsen et al., 2004). In this
study, and in another two that showed similar results,
there was no use of BMD measurement. Instead, the researchers sent out questionnaires or followed patients
through hospital registries to find out who suffered from
a fracture. In one of those studies, it was demonstrated that daily administration of 800 IU cholecalciferol,
an effective form of vitamin D3, together with calcium,
significantly reduced fractures by 30% compared to a placebo (Chapuy et al., 1994). The participants all lived in
nursing homes, so adherence was probably very high. The
large group (over 870 participants per arm) and similar
environment also gives weight to Chapuy’s study. Trivedi
et al. (2003) studied the effects of vitamin D3 given in
large, spaced doses on fracture reduction. They gave a
100,000 IU pill once every four months over a five-year
period. Adherence and collection of data was determined
through a questionnaire sent with each pill. A 20% reduction in all fractures and 30% at major osteoporotic sites
was found in the active group. These three studies imply
that preventing fractures can be achieved in an economic
fashion with vitamin D3. A difficulty with using fall data, as
these three studies did (some via questionnaire), is the
need to specify the type of fall, for example low or high
impact, and which body parts were affected and whether
there was a follow up by a doctor to see if the fall resulted in a fracture. Chapuy specifies whether there was a hip
fracture or not and Larsen obtained fracture information
from the Danish Hospital Registration Database. No sample of the questionnaires given out were provided, and
there may have been cases of fractures that the patients
did not report. In short, there is still a very strong case for
prescribing medication and not relying on vitamins alone.
Though the results are impressive at 30%, the remaining
70% (or a large portion) of participants who experienced
fractures would have benefited from medication.
Conclusion
Though osteoporosis affects millions of Americans, there
are many options to treat this disease. However, to ensure
proper treatment, each case requires a thorough review
of the patient’s circumstances. This includes the progression of bone loss, patient’s diet and lifestyle, and tolerance
to drugs. For those with osteopenia or just meeting the
threshold for osteoporosis it might be enough to engage
in supervised resistance exercise and to take vitamin D3
and calcium. Those with fractures or advanced osteoporosis will require drugs in addition to balance therapy.
Most clinicians will agree that the benefits of the current
drugs available outweigh the risks of adverse effects. It is
important to understand the risks of each drug to ensure
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that the more serious side effects, such as cardiovascular
issues, will not be a concern with a particular patient. It
is upon the clinician to have clear knowledge of the patient’s health status and know which drug is most suitable.
For example, though romosozumab causes the greatest
bone growth, it is not suitable for a patient at risk for
cardiovascular disease. Monitoring the progress of a
treatment and discussing any side effects experienced will
help the clinician further tailor the patient’s regimen. As
technology advances, we can look forward to new remedies in forms such as stem cell infusions and targeted
gene therapy. Until then, treating osteoporosis is a lifelong
process and patients can benefit from a combination of
pharmacologic and non-pharmacologic treatments.
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